At 11:27 AM; PI Industries quoted 7 per cent higher at Rs 3,340, as compared to 0.56 per cent rise in the S&P BSE Sensex. The average trading volumes at the counter jumped over four-fold today. A combined around 2 million equity shares changed hands on the NSE and BSE.
In Q3FY23, PI Industries’ reported 58 per cent year-on-year (YoY) jump in profit after tax to Rs 351.80 crore. The company’s revenue grew 19 per cent YoY to Rs 1,613 crore. CSM was up 23 per cent YoY to Rs 1,329 crore, led by volume growth of ~9 per cent and ~14 per cent coming from price, currency and favourable product mix. Domestic formulation was up 2 per cent YoY to Rs 285 crore, due to adverse weather condition coupled with higher channel inventory.
Gross margins were up by 73 bps YoY to 47.2 per cent while Ebitda (earnings before interest, taxes, depreciation, and amortization) margin expanded by 387 bps YoY to 25.7 per cent. The company said margin improved on account of favorable product mix and operating leverage.
In Q3FY23 earnings conference call, the management said in the last two to three years, new products contributed almost 17-18 per cent of total revenue. PI expects four to five products to be launched in the coming quarters. For new products to scale up, it generally takes three to four years. The company have robust order book of ~$1.8 billion and significant portion of revenue is from order book.
Analysts at ICICI Securities upgraded their rating on PI Industries from 'HOLD' to 'BUY' on the back of better growth outlook of the CSM business and consistency in performance.
Strong CSM order backlog of ~$1.8 billion bodes well for future growth. Proposed foray into pharma CDMO could expand revenue visibility further and diversify its revenue stream, to a certain extent. Launch of four to five new products every year in both segments and foray in horticulture in domestic segment to aid strong revenue growth are key triggers for future price performance, the brokerage firm said.
PI has levers in place to sustain near-term growth momentum, led by sustained growth momentum in the CSM business, driven by a strong (USD1.8b) order book, the rising pace of commercialization of new molecules, and a sales ramp-up in existing molecules, and product launches in the domestic market (seven new launches in 9MFY23), analysts at Motilal Oswal Financial Services said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app